Subscribe FREE to: Magazine | Newsletter | Linked In | Twitter Facebook


ODT Magazine


Search  


Latest News

ODT Magazine - RODMAN PUBLISHING CORP. Get it on Google Play

RTI Surgical Reports First Implantation of map3 Cellular Allogeneic Bone Graft




RTISurgical Inc. has used its map3 Cellular Allogeneic Bone Graft implant in a foot and ankle procedure for the very first time.

Michael Lyons, D.P.M., an associate member of the American College of Foot and Ankle Surgeons, performed the implantation during a medial column fusion procedure in Indiana. He used the implant’s chips allograft configuration, one of two configurations that will be available.

“Taking into account the published MAPC research, I decided to use map3 in a complex case with an immune-compromised patient because it would support the patient’s ability to heal,” Lyons said in a news release. “I was impressed by the ease of use—it required very little time to prepare with simple instructions for preparation. I will definitely use map3 again when it’s appropriate for the patient’s case.”

Map3 cellular allogeneic bone graft is a natural and safe alternative to autograft. Map3 provides a streamlined approach to bone grafting and supplies the three elements necessary for bone repair—osteogenesis, osteoinduction and osteoconduction—in a single allograft. Map3 incorporates multipotent adult progenitor cell-based (MAPC-based) technology with stem cells isolated from the same donor as the other bone material. The MAPC technology, licensed from Athersys Inc. for this orthopedic application, represents a distinctive type of stem cell with recognized angiogenic and immuno-modulatory properties. Map3 will be available in multiple configurations and sizes, providing bone grafting options for various bone repair, reconstruction and fusion procedures.

“Dr. Lyons’ use of map3 in a foot and ankle procedure is a new development following its use in spine procedures,” RTI resident/CEO Brian K. Hutchison said. “The MAPC-based technology offers the greatest potential to create high quality, innovative implants for our surgeons and their patients and will greatly enhance our company’s orthobiologics offerings. We anticipate a limited market release of the implant later this year.”

RTI Surgical is a global surgical implant developer. The company's products are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the United States and Europe.